In February, 2023 Imara merged with Enliven therapeutics (ELVN), with the resulting firm retaining Enliven’s name and development pipeline. Enliven is a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors to help patients with cancer live not only longer, but better.
| Website | https://www.enliventherapeutics.com/ |
| Ticker | IMRA |
| Revenue | $93.1 million |
| Employees | 11 (3 on RocketReach) |
| Founded | 2016 |
| Phone | +1 617-206-2020 |
| Technologies |
JavaScript
,
HTML
,
PHP
+30 more
(view full list)
|
| Industry | Biotechnology Research, Drug Manufacturing & Research, Collaboration, Pharmaceuticals, Genetics, Healthcare, Biotechnology, Health Care, Therapeutics |
| Keywords | Precision Oncology, Oncology, Cancer Therapeutics, Targeted Therapy, Clinical Stage, Cancer Research, Cancer Treatment, Drug Discovery, Drug Development, Immuno Oncology, Clinical Trials, Biotechnology, Molecular Medicine, Pharmaceutical, Biopharma, Next Generation, Therapeutics, Novel Therapies, Pipeline |
| Competitors | AstraZeneca, Novartis, Pfizer, Roche, GSK, Bristol Myers Squibb, Sanofi, Johnson & Johnson, Takeda, Amgen +38 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Imara Inc. employee's phone or email?
The Imara Inc. annual revenue was $93.1 million in 2026.
Vered Bisker-Leib is the Co-Founder of Imara Inc..
3 people are employed at Imara Inc..
Imara Inc. is based in Boston, Massachusetts.
The NAICS codes for Imara Inc. are [32, 32541, 3254, 325].
The SIC codes for Imara Inc. are [283, 28].